MedTrace Logo

Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial

NCT02049307 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2019-12-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the potential effectiveness of losartan (100mg daily) for reducing inflammation and improving immune recovery.

Conditions

Interventions

DRUG

Losartan 100mg daily

DRUG

Matching placebo

Sponsors & Collaborators

  • Hennepin Healthcare Research Institute

    lead OTHER

Principal Investigators

  • Jason Baker, M.D. · Hennepin Healthcare Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-16
Primary Completion
2018-12-14
Completion
2018-12-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02049307 on ClinicalTrials.gov